Overview of Rabemac-DSR

Rabemac-DSR is a prescription combination medicine administered orally, designed to manage symptoms related to both gastric acid excess and slow movement in the upper digestive tract. The active components are synthetic chemical compounds, confirming its origin as a chemically synthesized product.

Property	Description
Active Ingredients	Rabeprazole and Domperidone
Form	Oral Capsule (Delayed and Sustained Release, DSR)
Pharmacological Class	Proton Pump Inhibitor (PPI) combined with a Prokinetic Agent
Common Use (General Purpose)	Relieving symptoms related to acid reflux and impaired gastric motility
Origin	Synthetic chemical compounds

What Type of Medicine is Rabemac-DSR? (Identity and Classification)

Rabemac-DSR is an oral pharmaceutical that combines two distinct agents: a Proton Pump Inhibitor (PPI), Rabeprazole, and a Prokinetic Agent, Domperidone. This dual action, combining gastric acid suppression with motility enhancement, is clinically recognized as a strategy to address the two primary contributing factors to persistent reflux symptoms. The formulation is widely recognized in medical practice for its efficacy in providing comprehensive support for upper gastrointestinal health.

Composition and Form: What Does the DSR Capsule Contain?

The medicine is supplied as a specialized oral capsule that utilizes a Delayed and Sustained Release (DSR) formulation. This design is a distinguishing feature, ensuring the two active ingredients are released into the body over an extended period. The Rabeprazole component is enteric-coated to ensure its integrity against stomach acid. Concurrently, the Domperidone component is engineered for sustained release, maintaining its therapeutic effect and prolonged influence on gut contractions. This optimized delivery is crucial for maintaining consistent symptom control, such as relieving the frequent burning sensation of heartburn or the discomfort of bloating caused by slow gastric emptying.

What side effects are possible with Rabemac-DSR?

Possible Side Effects and Safety Information

The safety profile of Rabemac-DSR (Rabeprazole and Domperidone) is documented through official regulatory data, classifying adverse reactions by frequency and affected body system. This information is non-advisory and reflects findings from clinical studies.

Adverse Reaction Categories

Classification	Examples of Documented Side Effects
Common	Headache, Diarrhea, Nausea, Vomiting, Abdominal pain, Dizziness, Flatulence, Asthenia.
Uncommon	Insomnia, Somnolence, Nervousness, Dry mouth, Constipation, Rash, Peripheral edema.
Rare/Very Rare	Severe hypersensitivity reactions (e.g., Angioedema), Hepatic enzyme abnormalities, Jaundice, Acute Interstitial Nephritis, Extrapyramidal reactions.

Serious Adverse Reactions and Key Limitations

Serious Adverse Reactions (SARs) associated with the drug components include Severe Cardiac Arrhythmias (irregular heartbeat) and QT interval prolongation, primarily due to the Domperidone component. The risk of these serious cardiac events is a major regulatory concern.

Population-Specific Safety Constraints strictly limit use in certain patient groups:

Hepatic Impairment: The drug is contraindicated in cases of moderate to severe liver impairment.
Pregnancy and Lactation: Use is generally contraindicated or not recommended as the components can be excreted in human milk, and fetal risks cannot be excluded.

Duration-Related Risks associated with prolonged use of the Rabeprazole (PPI) component include an increased risk of osteoporosis-related fractures and Severe Hypomagnesaemia (low magnesium levels). The label also requires caution regarding Malignancy Exclusion, as symptom relief does not rule out the presence of gastric malignancy.

Overdose and Emergency Response

Rabemac-DSR Overdose and when to seek help

The official regulatory profile for this combination medicine’s overdose is largely defined by the severe risks and central nervous system (CNS) manifestations documented for the Domperidone component. Immediate medical attention is mandated in cases of suspected overdose.

Mandated Emergency Response Official government regulatory bodies require that emergency medical attention or contact with a Poison Control Center be sought immediately upon any suspicion of overdose. This action is required even if the individual remains asymptomatic.

Documented Clinical Manifestations and Risk Overdose manifestations may include CNS effects such as drowsiness, disorientation, and a confused state. Neurological findings can involve extrapyramidal reactions, such as uncontrolled movements or abnormal posture. A specific consideration notes these extrapyramidal symptoms are more likely to occur especially in children. The primary severe risk involves the potential for QT interval prolongation on the electrocardiogram (ECG), which is associated with an increased risk of serious ventricular arrhythmias and sudden cardiac death.

Management and Monitoring Due to the potential for cardiac risk, ECG monitoring should be undertaken following a suspected overdose. No specific antidote is known; therefore, management is restricted to supportive and symptomatic treatment. Procedural interventions, such as gastric lavage and the administration of activated charcoal, may be utilized as appropriate.

Therapeutic Uses of Rabemac-DSR

Main Uses and Benefits of Rabemac-DSR

Rabemac-DSR is a combination medication primarily used to manage conditions related to excessive stomach acid and gastrointestinal motility. By combining an acid-suppressing agent with a prokinetic, it addresses both the production of acid and the movement of food through the digestive tract.

Gastroesophageal Reflux Disease (GERD)

The medication is frequently utilized for the treatment of gastroesophageal reflux disease, commonly known as acid reflux. In this condition, stomach acid flows back into the esophagus, causing irritation. The treatment helps alleviate symptoms such as heartburn and regurgitation by reducing acid levels and preventing the backward flow of gastric contents.

Peptic Ulcer Disease

Rabemac-DSR is used in the management of ulcers in the stomach or the upper part of the small intestine (duodenum). By decreasing acid production, the medication creates an environment that allows the mucosal lining of the digestive tract to recover and heal.

Management of Functional Dyspepsia

For individuals experiencing persistent indigestion or discomfort in the upper abdomen, this medication helps improve gastric motility. It assists in moving food more efficiently through the stomach into the intestines, which can reduce sensations of fullness, bloating, and upper abdominal pain.

Relief from Acid-Related Nausea and Vomiting

The inclusion of a prokinetic component makes this combination effective for patients whose acid-related conditions are accompanied by nausea or vomiting. It helps stabilize the digestive rhythm, providing relief from the physical discomfort associated with slow gastric emptying.

Eligibility and Restrictions for Use

Who can and cannot use Rabemac-DSR?

Rabemac-DSR is subject to strict eligibility rules and is contraindicated in several patient populations, primarily due to risks associated with the Domperidone component. The medicine must not be used by individuals with a known hypersensitivity to Rabeprazole, Domperidone, or related benzimidazoles.

Absolute Contraindications

Absolute contraindications include patients with moderate or severe hepatic impairment and those with existing cardiac risk factors, such as QTc prolongation, congestive heart failure, or significant electrolyte disturbances (like hypokalemia). Use is also prohibited in patients with a prolactin-releasing pituitary tumor or conditions where stimulating gut motility is harmful, such as gastrointestinal hemorrhage or obstruction.

Age and Physiological Status

Adults are the primary eligible population. Use is not recommended for children, typically those under 12 years of age, due to insufficient safety data. Patients older than 60 years require caution due to an increased cardiac risk. The medicine is contraindicated during both pregnancy and breastfeeding. Furthermore, the possibility of gastric malignancy must be excluded before use, and use in severe renal impairment requires special regulatory consideration.

What should I know about interactions with other medicines?

The official regulatory profile for this combination medicine is defined by two primary interaction patterns: pH-related effects from Rabeprazole and metabolic/pharmacodynamic effects from Domperidone.

Co-administration is formally contraindicated with medicines that prolong the QTc interval and with potent CYP3A4 inhibitors, such as oral ketoconazole, due to the risk of increasing Domperidone plasma concentrations. The Rabeprazole component is restricted from co-use with Rilpivirine and Erlotinib.

Exposure-Modifying and Pharmacodynamic Interactions

Due to Rabeprazole's effect on gastric acidity, medicines whose absorption requires an acidic environment (e.g., Digoxin, Itraconazole, Iron Salts) may have reduced plasma levels. Conversely, Rabeprazole may elevate and prolong the serum concentration of Methotrexate and is associated with increased International Normalized Ratio ( INR) in patients taking Warfarin. Anticholinergic drugs may antagonise the prokinetic effect of Domperidone.

Administration Constraints and Specific Substances

Antacids or antisecretory agents must not be taken simultaneously with the Domperidone component as they lower its bioavailability. For the Rabeprazole component, chronic daily use ( e.g., over 3 years) is associated with a risk of Cyanocobalamin ( Vitamin B-12) malabsorption. Use is contraindicated in patients with moderate or severe hepatic impairment.

Mechanism of Action

Rabemac-DSR is a combination product that exerts its action through two distinct, yet complementary, pharmacodynamic mechanisms targeting the upper gastrointestinal system.

Irreversible H^+/ K^+- ATPase Inhibition

The Rabeprazole component operates by undergoing acid-dependent activation in the gastric parietal cells, forming an irreversible covalent bond with the H^+/ K^+- ATPase enzyme (the proton pump). This action physically disables the enzyme, preventing the final step of hydrochloric acid secretion, which limits the output of hydrogen ions ( H^+).

Peripheral D2 Receptor Blockade and Motility Increase

The Domperidone component acts primarily as an antagonist at peripheral D2/ D3 dopamine receptors located in the enteric nervous system and the Chemoreceptor Trigger Zone ( CTZ). This blockade relieves the inhibitory tone on cholinergic nerves, increasing acetylcholine release to increase smooth muscle contraction and tone, resulting in accelerated gastric emptying and increased pressure in the Lower Esophageal Sphincter ( LES).

Dual-Mechanism Synergy

The drug's overall profile relies on a coordinated physiological effect: the H^+/ K^+- ATPase inhibition reduces the acidity of stomach content, while the peripheral D2 antagonism simultaneously increases the physical clearance of that content and blocks signal transduction from the CTZ.

Dosage and Administration Information

How to Use Rabemac-DSR: Administration Guidelines

Rabemac-DSR (Rabeprazole 20 mg and Domperidone 30 mg SR) is an oral combination medicine supplied as a Delayed and Sustained Release (DSR) capsule. The following instructions detail the standardized procedures for administration.

Administration and Dosage Rules

Usage Parameter	Instruction
Route & Form	Oral capsule (must be swallowed whole).
Timing (Meals)	Should be taken before meals for optimal effect.
Standard Dose	One capsule (20 mg/30 mg SR) once daily. The dose may be adjusted up to a maximum of two capsules daily, as per prescribing information.
Duration Constraint	The use of the Domperidone component is typically limited to the shortest duration necessary, generally not exceeding one week.
Missed Dose	A missed dose should be omitted, and the patient should continue with the next scheduled dose. The dose must not be doubled.
Special Handling	The DSR capsule must not be chewed, crushed, or split to preserve the integrity of the delayed and sustained release components.

Population-Specific Use

Children and Adolescents: The combination product is not recommended for use in children due to a lack of sufficient data on safety and efficacy.
Renal Impairment: For patients with severe renal impairment, the dosing frequency for the Domperidone component must be reduced (e.g., to once or twice daily) due to prolonged elimination.
Hepatic Impairment: No dosage adjustment is generally required for the Rabeprazole component in patients with mild to moderate hepatic impairment.

Recent Clinical Evidence

Research evidence / Overview of studies for Rabemac-DSR

Evidence for Use in Gastroesophageal Reflux Disease (GERD) with Motility Issues

Research has explored the use of the Rabeprazole-Domperidone combination in adults with Gastroesophageal Reflux Disease (GERD) in contexts where the research explored outcomes related to gastric motility alongside acid-related symptoms. Studies conducted during periods of increased symptom activity examined patient-reported outcomes related to physical discomfort, primarily focusing on the frequency and severity of heartburn and the endoscopic healing rates that were monitored.

The available research includes Systematic Reviews and Meta-Analyses which compile data from multiple Randomized Controlled Trials (RCTs). Findings describe patterns observed in these studies where the combination was evaluated in research exploring changes in symptoms compared to using only the acid-reducing component (Rabeprazole). The research also describes how endoscopic healing rates were monitored in the observed populations.

Evidence for Use in Functional Dyspepsia (FD)

The combination was evaluated in research exploring outcomes related to Functional Dyspepsia (FD). Studies focused on episodes where symptoms become more noticeable, examining outcomes related to systemic or functional imbalance, such as measures of gastric emptying time.

Research has explored short-term symptom changes, with studies observing responses over defined time intervals, typically 4 to 8 weeks. Studies focused on patient-reported outcomes describing perceived discomfort, such as nausea, bloating, and epigastric pain. Findings describe patterns observed in the studies related to how these symptoms evolved in the observed populations.

Long-Term Studies and Follow-Up

The majority of the core evidence, particularly the larger, randomized Randomized Controlled Trials (RCTs), focused on providing insight into short-term changes. The typical follow-up durations used in research exploring short-term symptom changes range from 4 to 12 weeks.

This means that long-term effects are not fully established. There is limited information for long-term outcomes regarding the sustained symptomatic change or the durability of the reported patterns over periods of six months or a year. Research provides context but not individual predictions about how patients may experience symptom management beyond the defined time intervals of the core studies.

What is Still Uncertain About the Research for Rabemac-DSR

While research provides context for short-term symptom monitoring, several research limitation frames exist. Evidence quality varies across studies, and the data show patterns related to patient-reported experiences that may be influenced by regional variations in diagnosis and care. One key gap is the limited information for long-term outcomes and the lack of comprehensive comparative evidence against all other potential therapeutic options.

Key Studies & References

MedlinePlus: Rabeprazole

Frequently Asked Questions (FAQ)

Common questions about Rabemac-DSR (FAQ)

Q: What is the main thing Rabemac-DSR is used for?

According to official product information, Rabemac-DSR is primarily used to manage conditions like Gastroesophageal Reflux Disease (GERD). It is intended for situations where symptoms, such as heartburn, require both a reduction in stomach acid and improved movement in the upper digestive tract.

Q: Why do some people take Rabemac-DSR when they don't have ulcers?

The medicine is indicated for several conditions beyond ulcers. Official documents state that it is used for managing symptoms associated with GERD and can also be used for certain types of Non-ulcer Dyspepsia (indigestion). The goal is to address acid issues alongside slow stomach emptying.

Q: Is Rabemac-DSR a type of antibiotic?

No. Official documents classify Rabemac-DSR as a combination of two distinct types of medicine: a Proton Pump Inhibitor (Rabeprazole) and a Prokinetic Agent (Domperidone). It does not belong to the class of antibiotics.

Q: Are there other drugs similar to Rabemac-DSR that treat the same problems?

Yes, other medicines exist that address similar issues. The Rabeprazole component belongs to the class of medicines called Proton Pump Inhibitors (PPIs), which includes several other medicines. Similarly, the Domperidone component belongs to the class of Dopamine Receptor Antagonists used to assist with gut movement.

Q: Is it true that Rabemac-DSR can affect calcium or vitamin levels?

Studies and official information indicate that long-term use of the Rabeprazole component, typically over a year, is associated with a risk of Vitamin B-12 malabsorption and severely low magnesium levels (hypomagnesaemia). Regulatory documents state that low calcium levels (hypocalcemia) are a potential concern that has been noted.

Q: What is the difference between Rabemac-DSR and regular Rabemac?

Rabemac-DSR is a combination medicine that contains two active ingredients: Rabeprazole (for acid) and Domperidone (for motility) in a specialized capsule. Regular Rabemac, when referenced as a single agent, typically refers only to the Rabeprazole component for acid suppression.

Q: How quickly should I expect to feel a difference after starting Rabemac-DSR?

Regulatory information indicates that the acid-reducing effect of the Rabeprazole component often begins within one hour of administration. Significant changes in stomach acidity were noted in studies after one day of treatment, with more complete effects reported after seven days.

Q: Is it necessary to avoid certain foods while using Rabemac-DSR?

Official advice states that making certain dietary modifications can support the treatment process. This may include dietary modifications focused on minimizing foods and drinks that are commonly known to trigger acid reflux symptoms, such as highly acidic or spicy foods, caffeine, and alcohol.

Q: How does Rabemac-DSR compare to over-the-counter stomach medicines?

The Rabeprazole component is a Proton Pump Inhibitor (PPI). It works by physically blocking the acid-producing pumps in the stomach lining. This is a different mechanism than that of over-the-counter options like antacids, which primarily neutralize existing acid, or H2 blockers, which reduce acid signal production.

Q: Does Rabemac-DSR make you gain or lose weight?

Weight change is not listed as a common or uncommon side effect in core regulatory summaries for the Rabeprazole component. The Domperidone component has been noted in certain data contexts to be associated with weight gain in individuals.

Q: Is it possible to be allergic to Rabemac-DSR?

Yes, regulatory documents state that the medicine is contraindicated if a patient has a known hypersensitivity to Rabeprazole, Domperidone, or any of the ingredients in the capsule.

Q: Is there a risk of becoming dependent on Rabemac-DSR?

Regulatory documents generally do not classify this medicine as dependency-forming. However, sudden discontinuation of the Domperidone component, particularly after high-dose use, has been associated with severe neuropsychiatric adverse events such as agitation or anxiety.

Q: How long does the effect of Rabemac-DSR last after a single dose?

The action of the Rabeprazole component reflects the prolonged action achieved through the sustained inactivation of the acid pump. The Domperidone component is designed as a sustained-release formulation intended to maintain its therapeutic effect over an extended period.

Q: What happens if Rabemac-DSR is taken longer than prescribed?

Taking the medicine for longer than the recommended duration increases the risk of duration-related side effects. These risks include an increased chance of bone fractures and severe low magnesium levels (hypomagnesaemia) from the Rabeprazole component, and an increased cardiac risk associated with the Domperidone component.

Q: What happens when you stop taking Rabemac-DSR?

Official information indicates that stopping the medicine too soon may lead to the return or worsening of your original symptoms. The Domperidone component is typically recommended for the shortest duration necessary, often not exceeding one week.

Q: Does Rabemac-DSR interact with herbal medicines?

Official guidance notes that there is not enough information to guarantee that other complementary medicines or herbal remedies are safe to take with the Domperidone component. Some herbal remedies may also interact and potentially worsen side effects.

Q: Are there specific vitamins or supplements that are known to interact with Rabemac-DSR?

Official guidance states there is limited information to confirm safety when taking supplements with the Domperidone component. The Rabeprazole component may also affect the absorption of Vitamin B-12 and Iron Salts, which is noted in regulatory documents.

Q: Are there specific times of day that Rabemac-DSR is usually taken?

The medicine is generally indicated to be taken once daily. The Domperidone component is usually taken before meals. Some combination product labels may specify a general daily time, such as in the morning, to fit the before-meal requirement.

How should Rabemac-DSR be stored and disposed of?

Official Storage and Disposal Requirements

Rabemac-DSR must be stored strictly according to regulatory guidelines to protect the integrity of the capsule and its active components.

Condition	Requirement (Regulatory Standard)
Temperature	Store below 25 C or 30 C (room temperature).
Protection	Keep protected from both light and moisture in a cool and dry place.
Packaging	Keep in the original container and ensure it is tightly closed.

The medicine must be stored out of the sight and reach of children and pets. Unused or expired Rabemac-DSR must be disposed of according to local requirements to prevent accidental consumption and avoid environmental contamination. Do not use the product past its expiry date.

Rabemac-DSR